(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 15.25% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Penumbra's revenue in 2026 is $1,333,798,000.On average, 22 Wall Street analysts forecast PEN's revenue for 2026 to be $62,620,321,023, with the lowest PEN revenue forecast at $59,487,346,863, and the highest PEN revenue forecast at $67,868,052,741. On average, 20 Wall Street analysts forecast PEN's revenue for 2027 to be $71,275,162,140, with the lowest PEN revenue forecast at $66,654,025,254, and the highest PEN revenue forecast at $79,577,543,664.
In 2028, PEN is forecast to generate $79,969,165,434 in revenue, with the lowest revenue forecast at $76,013,785,557 and the highest revenue forecast at $85,686,843,276.